Zydus Arm Sentynl Secures FDA Approval for First-Ever Menkes Disease Therapy

Zydus Lifesciences’ US-based subsidiary, Sentynl Therapeutics Inc., has received US FDA approval for ZYCUBO® (copper histidinate), marking a major milestone in rare disease treatment. ZYCUBO becomes the first and only FDA-approved therapy for Menkes disease, a rare and often fatal genetic disorder affecting pediatric patients. Menkes disease is caused by mutations in the ATP7A gene, leading to impaired copper absorption and severe neurological complications. Until now, there was no approved treatment in the United States, with most untreated patients not surviving beyond three years of age. Clinical data supporting the approval showed nearly an 80% reduction in mortality risk when ZYCUBO was administered early. Median overall survival improved sharply to 177.1 months, compared with 17.6 months in untreated patients, highlighting the therapy’s life-extending potential. ZYCUBO is a daily subcutaneous injectable copper replacement therapy designed to restore copper balance in the body. The drug has previously received Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations, underlining its clinical significance. The approval strengthens Zydus Lifesciences’ global rare disease portfolio and reinforces its innovation-led strategy in specialty and orphan therapies, while opening a meaningful long-term opportunity in niche, high-impact treatments. Disclaimer: This article is for informational purposes only and does not constitute investment advice.